Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Galderma Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: $22.9B

Website: http://www.galderma.com/

Clinical Trials

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Adapalene

First Posted Date: 2008-04-18

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 51

Registration Number: NCT00660985

Locations: 🇺🇸
DermResearch, Inc., Austin, Texas, United States
🇺🇸
J&S Studies, Inc., College Station, Texas, United States

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: clobetasol propionate spray 0.05%
Drug: calcitriol ointment

First Posted Date: 2008-04-15

Last Posted Date: 2022-08-23

Lead Sponsor: Galderma R&D

Target Recruit Count: 305

Registration Number: NCT00658788

Locations: 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸
MedaPhase, Inc., Newnan, Georgia, United States
🇺🇸
Gwinnett Clinical Research Center, Inc, Snellville, Georgia, United States

and more 9 locations

Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

Phase 3

Completed

Conditions: Photoaging

Interventions: Drug: tretinoin 0.05% emollient cream
Drug: adapalene gel, 0.3%

First Posted Date: 2008-03-31

Last Posted Date: 2022-08-01

Lead Sponsor: Galderma R&D

Target Recruit Count: 30

Registration Number: NCT00647556

Locations: 🇺🇸
University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Adapalene Lotion Vehicle
Drug: Adapalene lotion 0.1%

First Posted Date: 2008-01-23

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 1075

Registration Number: NCT00598832

Locations: 🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸
Scott Dinehart, Little Rock, Arkansas, United States
🇺🇸
Dermatology and Laser Center, Marina Del Rey, California, United States

and more 31 locations

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Adapalene lotion 0.1%
Drug: Adapalene Lotion Vehicle

First Posted Date: 2008-01-23

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 1067

Registration Number: NCT00599521

Locations: 🇺🇸
University of California, San Diego, California, United States
🇺🇸
Dermatology Specialists, Inc., Vista, California, United States
🇺🇸
Cherry Creek Dermatology, Denver, Colorado, United States

and more 30 locations

Treatment of Patients With Blepharitis and Facial Rosacea

Phase 2

Completed

Conditions: Meibomianitis
Blepharitis
Dry Eye

Interventions: Drug: COL-101 (doxycycline, USP) capsules
Drug: placebo

First Posted Date: 2007-11-20

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 70

Registration Number: NCT00560703

Locations: 🇺🇸
Pleasant Valley Ophthalmology, Little Rock, Arkansas, United States
🇺🇸
Warren Scherer, MD, Naples, Florida, United States
🇺🇸
Kentucky Lions Eye Center, Louisville, Kentucky, United States

and more 5 locations

Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease

Conditions: Field Actinic Keratoses
Basal Cell Carcinoma
Bowen's Disease

First Posted Date: 2007-09-26

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Registration Number: NCT00535080

Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma

Phase 4

Completed

Conditions: Melasma

First Posted Date: 2007-07-12

Last Posted Date: 2021-02-17

Lead Sponsor: Galderma R&D

Target Recruit Count: 340

Registration Number: NCT00500162

Locations: 🇧🇷
UNIFESP - Universidade Federal de São Paulo, Sao Paulo, Brazil
🇲🇽
Hospital General de México - Servicio de Dermatología, Mexico City, Mexico

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Phase 3

Completed

Conditions: Basal Cell Carcinoma

Interventions: Drug: Metvix® cream

First Posted Date: 2007-05-15

Last Posted Date: 2023-01-05

Lead Sponsor: Galderma R&D

Target Recruit Count: 102

Registration Number: NCT00473343

Locations: 🇦🇺
Department of Dermatology, St. George Hospital, Kogarah, New South Wales, Australia
🇦🇺
South East Dermatology, The Belmont Specialist Clinic, Carnia, Queensland, Australia
🇦🇺
Department of Dermatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 4 locations

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

Phase 4

Completed

Conditions: Melasma

Interventions: Drug: Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels

First Posted Date: 2007-05-14

Last Posted Date: 2022-07-29

Lead Sponsor: Galderma R&D

Target Recruit Count: 20

Registration Number: NCT00472966

Locations: 🇺🇸
Skin Care Research, Inc., Boca Raton, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy